Further discussion on the association between desmoglein 2 and tumor size of non-small cell lung cancer
- PDF / 514,921 Bytes
- 3 Pages / 595.276 x 790.866 pts Page_size
- 42 Downloads / 158 Views
LETTER TO THE EDITOR
Further discussion on the association between desmoglein 2 and tumor size of non‑small cell lung cancer Siyuan Hao1 · Jiayi Liu1 · Jia Ma1 Received: 20 September 2020 / Accepted: 10 November 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract We have read the article by Cai et al. and find there is a discrepancy between their data and conclusion. Their statement, “Specifically, DSG2 expression was associated with tumor size”, is not supported by their own clinicopathological data and analysis. After reviewing some similar articles, we also found no available evidence showed a statistically significant association between them. Therefore, we would like to suggest Cai et al. to rectify the results they published. Keywords Non-small-cell lung cancer · Desmoglein 2 · Clinicopathological features Dear Editor, With great regard, we read the article by Cai et al. regarding the Desmoglein‐2 is overexpressed in non‐small cell lung cancer tissues and its knockdown suppresses NSCLC growth by regulation of p27 and CDK2 (Cai et al. 2017a). We really appreciate the interesting observation of their conclusion. However, after reading this article, we would like to point out a statistic mistake in data analysis. Lung cancer has drawn plenty of attention in cancer research recently because of its great harm to human health (Du et al. 2020; Li et al. 2020; Zhou et al. 2020), especially non-small-cell lung cancer (Chen et al. 2020; Kashiwabara et al. 2020; Lathwal et al. 2020). Desmoglein 2 (DSG2) has been discovered as a promising biomarker in various human cancers (Han et al. 2018; Qin et al. 2020; Yashiro et al. 2006), including non-small-cell lung cancer (Jin et al. 2020; Sun et al. 2020; Xiao et al. 2017). We included the study of Cai et al. in a systematic review and meta-analysis which has been registered on PROSPERO platform (https://www. crd.york.ac.uk/prospero/) with an ID of CRD4202020220. Cai et al. aimed to assess the prognostic and clinicopathology significance of DSG2 in non-small-cell lung cancer (Cai * Jia Ma [email protected] 1
State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, No 14th, 3rd section, Renmin South Road, Chengdu 610041, China
et al. 2017b) and its mechanism. The authors concluded in results that “Specifically, DSG2 expression was associated with tumor size (Table 1, P = 0.044).” We argue that this statement of Cai et al. is not supported by their own data and analysis. In their cohort study, 70 patients were eligible to participate in the study, whose clinicopathology was recorded, and comprehensively reported in Table 1 in their original article (Table 1). However, firstly, as this table shows, in the row of “Tumor size (cm)”, the total number of patients is 66 but not 70. Secondly, we noticed they reported that the total number of patients whose tumor size was not more than 4 cm is 41, but it is not the sum of the following data: 23 and 6. Similar
Data Loading...
